Ongoing studies for the secondary prevention of CAT in adult patients
| Study . | Study design . | Intervention . | Status . |
|---|---|---|---|
| Apixaban in Preventing Secondary Cancer-Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy (NCT03080883) | RCT | Lower-dose apixaban vs higher-dose apixaban | Recruiting |
| API-CAT STUDY for APIxaban Cancer-Associated Thrombosis (API-CAT; NCT03692065) | RCT | Apixaban 2.5 mg twice daily vs 5 mg twice daily | Recruiting |
| Study . | Study design . | Intervention . | Status . |
|---|---|---|---|
| Apixaban in Preventing Secondary Cancer-Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy (NCT03080883) | RCT | Lower-dose apixaban vs higher-dose apixaban | Recruiting |
| API-CAT STUDY for APIxaban Cancer-Associated Thrombosis (API-CAT; NCT03692065) | RCT | Apixaban 2.5 mg twice daily vs 5 mg twice daily | Recruiting |